What is the address of CALISTHERAPY?

The registered office of CALISTHERAPY is located at Vennenstraat 26, 3920 Lommel.

Is CALISTHERAPY still active?

Yes. According to the CBE (1 October 2026) CALISTHERAPY is active, legal situation “Normale toestand”, started on 19 February 2024.

Is CALISTHERAPY registered on Peppol?

Yes, CALISTHERAPY is registered on the Peppol network with ID 0208:1006166548.

What is the enterprise number of CALISTHERAPY?

The enterprise number of CALISTHERAPY is BE1006166548.

When was CALISTHERAPY founded?

CALISTHERAPY was founded on 19 February 2024.

Who are the directors of CALISTHERAPY?

According to the 2025 annual accounts, the directors of CALISTHERAPY are: Mathias Vaesen.

Is CALISTHERAPY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 February 2024; 2 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CALISTHERAPY make in 2025?

CALISTHERAPY posted a profit after taxes of € 37,715 in financial year 2025.

What is the revenue of CALISTHERAPY?

As a small company, CALISTHERAPY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 60,567.

CALISTHERAPY (Private Limited) - Lommel - BE1006166548

Dossier CALISTHERAPY, printed on 1 October 2026 from databakkes.be/en/1006166548/calistherapy. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CALISTHERAPY from Lommel, company number BE1006166548, closed financial year 2025 with a result of € 37,715 after tax. For that financial year CALISTHERAPY recorded a gross margin of € 60,567 and equity of € 69,069. Compared with financial year 2024, the result moved from € 26,354 to € 37,715. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 69,069

▲ 120% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 37,715

▲ 43% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,758

▲ 86% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 64,069.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 1,920 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 1,920

▲ 20% vs 2024

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 43,595

▲ 189% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 31,739

€ 6,676 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 8,854

▼ 35% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 4,505

▼ 51% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2024	2025	Change 2024 → 2025
Gross margin	€ 38,764 Gross margin 2024: € 38,764 First fiscal year in the series	€ 60,567 Gross margin 2025: € 60,567 ▲ 56% vs 2024 (€ 38,764) Favourable step	▲ 56%
Profit after taxes	€ 26,354 Profit after taxes 2024: € 26,354 First fiscal year in the series	€ 37,715 Profit after taxes 2025: € 37,715 ▲ 43% vs 2024 (€ 26,354) Favourable step	▲ 43%
Equity	€ 31,354 Equity 2024: € 31,354 First fiscal year in the series	€ 69,069 Equity 2025: € 69,069 ▲ 120% vs 2024 (€ 31,354) Favourable step	▲ 120%
Total debts	€ 22,991 Total debts 2024: € 22,991 First fiscal year in the series	€ 48,213 Total debts 2025: € 48,213 ▲ 110% vs 2024 (€ 22,991) Unfavourable step	▲ 110%
Cash	€ 37,971 Cash 2024: € 37,971 First fiscal year in the series	€ 70,758 Cash 2025: € 70,758 ▲ 86% vs 2024 (€ 37,971) Favourable step	▲ 86%
Land & buildings	-	€ 1,932 Land & buildings 2025: € 1,932 First fiscal year in the series
Retained profit	€ 26,354 Retained profit 2024: € 26,354 First fiscal year in the series	€ 64,069 Retained profit 2025: € 64,069 ▲ 143% vs 2024 (€ 26,354) Favourable step	▲ 143%
Bank debt	€ 0 Bank debt 2024: € 0 First fiscal year in the series	€ 31,739 Bank debt 2025: € 31,739 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 54,344 Balance sheet total 2024: € 54,344 First fiscal year in the series	€ 117,282 Balance sheet total 2025: € 117,282 ▲ 116% vs 2024 (€ 54,344) Unchanged	▲ 116%

Key figures of CALISTHERAPY, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CALISTHERAPY?

What happened at CALISTHERAPY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 37,715 (▲ 43% vs 2024). Source: NBB ↗
Feb 19, 2024 New establishment in Lommel. KBO
Feb 19, 2024 Start of the company according to the CBE. KBO

In short

From € 26,354 profit in 2024 to € 37,715 profit in 2025.

Paid € 21,289 in corporate taxes since 2024.

Best year ever: 2025, with € 37,715 profit.

Original PDFs at the National Bank ↗

A new publication or filing at CALISTHERAPY? We notify you, reason included.

Follow CALISTHERAPY

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Mathias Vaesen

CALISTHERAPY

Behind CALISTHERAPY is Mathias Vaesen.

See the full network in the app

Directors

According to the 2025 annual accounts

Mathias Vaesen

Administrator-manager

Establishments

Establishment units

Physical locations of this company

Registered office

Vennenstraat 26

3920 Lommel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 1006.166.548
VAT number: BE 1006.166.548
Registered office: Vennenstraat 26, 3920 Lommel
Names & denominations: CALISTHERAPY
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 February 2024
Peppol: Active · Active since 18 Nov 2025

View on CBE Public ↗ Annual accounts (NBB) ↗